Elimination of lipid levels from quality measures: implications and alternatives.
New York City Health and Hospitals Corporation, New York, New York2Department of Population Health, NYU School of Medicine, New York, New York.
Nicholas W
NW
Stine
New York City Health and Hospitals Corporation, New York, New York2Department of Population Health, NYU School of Medicine, New York, New York.
Dave A
DA
Chokshi
D060866:Accountable Care Organizations / Q000592:standards*; D014487:Centers for Medicare and Medicaid Services, U.S.; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D019984:Quality Indicators, Health Care; D018570:Risk Assessment; D014481:United States
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids